Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RTNova
- Development stage
- Preclinical
- Lead developer
- Calidi Biotherapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intravenous
01
Overview
RTNova (CLD-400) is a virotherapy platform developed by Calidi Biotherapeutics for the systemic treatment of cancer, particularly lung cancer and metastatic solid tumors. The therapy utilizes a specially engineered, tumor-selective vaccinia virus strain that produces enveloped vaccinia viruses (envRTs), which are designed to resist humoral immunity. This enables the therapy to systemically target and destroy tumor cells while also modifying the tumor microenvironment by expressing specific proteins within tumors. The approach aims to provide a universal treatment option for various tumor types.
- Brand names
- RTNova
- Other names
- RTNovaCLD-400CLD400CLD 400
Beyond the preview
Go deeper on RTNova.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RTNova.